SciSparc Ltd. (NASDAQ: SPRC) announced that Clearmind Medicine Inc. (OTCPK:CMNDF) (CSE:CMND) (FSE:CWY0), has filed a provisional patent application related to metabolic syndromes including obesity, regarding the company's collaboration with Clearmind.

The patent application is the third of the collaboration, each referring to the proprietary combination of SciSparc's Palmitoylethanolamide (PEA), the active ingredient of its proprietary CannAmide (for treating obesity and its related metabolic disorders) and Clearmind's MEAI, a novel proprietary psychedelic treatment for various addictions and based on research at the Hebrew University.

"Our collaboration with Clearmind focuses on treating different addictions and …

Full story available on Benzinga.com